Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy

Antonella Castagna; Stefano Rusconi; Roberto Gulminetti; Stefano Bonora; Giovanni Mazzola; Maria E. Quiros-Roldan; Giuseppe V. De Socio; Nicoletta Ladisa; Sinibaldo Carosella; Annamaria Cattelan; Simona Di Giambenedetto; Maurizio Mena; Andrea Poli; Laura Galli; Agostino Riva

doi:10.1097/QAD.0000000000002188

Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy

Antonella Castagna, Stefano Rusconi, Roberto Gulminetti, Stefano Bonora, Giovanni Mazzola, Maria E. Quiros-Roldan, Giuseppe V. De Socio, Nicoletta Ladisa, Sinibaldo Carosella, Annamaria Cattelan, Simona Di Giambenedetto, Maurizio Mena, Andrea Poli, Laura Galli, Agostino Riva

Risultato della ricerca: Contributo in rivista › Articolo in rivista

4 Citazioni (Scopus)

Abstract

: We evaluated the efficacy and safety of a two-drug regimen including dolutegravir (DTG) and unboosted atazanavir (uATV) in 151 HIV-1 infected patients with HIV-RNA of more than 50 copies/ml. During a median follow-up of 62 (42-97) weeks, two virological failures (1%) and 13 treatment discontinuations (9%) occurred; the 48-week probability of virological failure was 0.8% (95% confidence interval 0.2-5.6%). Switch to DTG + uATV may represent a boosting and transcriptase reverse inhibitors sparing otion in individuals with long exposure to antiretroviral therapy and risk of cardiovascular disease.

Lingua originale	English
pagine (da-a)	1256-1260
Numero di pagine	5
Rivista	AIDS
Volume	33
DOI	https://doi.org/10.1097/QAD.0000000000002188
Stato di pubblicazione	Pubblicato - 2019

Keywords

Health Policy
Infectious Diseases
Pharmacology (medical)
antiretroviral therapy
dolutegravir
dual therapy
switch strategy

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1097/QAD.0000000000002188

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Castagna, A., Rusconi, S., Gulminetti, R., Bonora, S., Mazzola, G., Quiros-Roldan, M. E., De Socio, G. V., Ladisa, N., Carosella, S., Cattelan, A., Di Giambenedetto, S., Mena, M., Poli, A., Galli, L., & Riva, A. (2019). Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy. AIDS, 33, 1256-1260. https://doi.org/10.1097/QAD.0000000000002188

@article{bccb04dcc0214666acfe3be8e31c148c,

title = "Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy",

abstract = ": We evaluated the efficacy and safety of a two-drug regimen including dolutegravir (DTG) and unboosted atazanavir (uATV) in 151 HIV-1 infected patients with HIV-RNA of more than 50 copies/ml. During a median follow-up of 62 (42-97) weeks, two virological failures (1%) and 13 treatment discontinuations (9%) occurred; the 48-week probability of virological failure was 0.8% (95% confidence interval 0.2-5.6%). Switch to DTG + uATV may represent a boosting and transcriptase reverse inhibitors sparing otion in individuals with long exposure to antiretroviral therapy and risk of cardiovascular disease.",

keywords = "Health Policy, Infectious Diseases, Pharmacology (medical), antiretroviral therapy, dolutegravir, dual therapy, switch strategy, Health Policy, Infectious Diseases, Pharmacology (medical), antiretroviral therapy, dolutegravir, dual therapy, switch strategy",

author = "Antonella Castagna and Stefano Rusconi and Roberto Gulminetti and Stefano Bonora and Giovanni Mazzola and Quiros-Roldan, {Maria E.} and {De Socio}, {Giuseppe V.} and Nicoletta Ladisa and Sinibaldo Carosella and Annamaria Cattelan and {Di Giambenedetto}, Simona and Maurizio Mena and Andrea Poli and Laura Galli and Agostino Riva",

year = "2019",

doi = "10.1097/QAD.0000000000002188",

language = "English",

volume = "33",

pages = "1256--1260",

journal = "AIDS",

issn = "0269-9370",

publisher = "- Wolters Kluwer Health, Inc. -London : Lippincott Williams & Wilkins -London : Gower Academic Journals, 1987-",

}

Castagna, A, Rusconi, S, Gulminetti, R, Bonora, S, Mazzola, G, Quiros-Roldan, ME, De Socio, GV, Ladisa, N, Carosella, S, Cattelan, A, Di Giambenedetto, S, Mena, M, Poli, A, Galli, L & Riva, A 2019, 'Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy', AIDS, vol. 33, pagg. 1256-1260. https://doi.org/10.1097/QAD.0000000000002188

TY - JOUR

T1 - Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy

AU - Castagna, Antonella

AU - Rusconi, Stefano

AU - Gulminetti, Roberto

AU - Bonora, Stefano

AU - Mazzola, Giovanni

AU - Quiros-Roldan, Maria E.

AU - De Socio, Giuseppe V.

AU - Ladisa, Nicoletta

AU - Carosella, Sinibaldo

AU - Cattelan, Annamaria

AU - Di Giambenedetto, Simona

AU - Mena, Maurizio

AU - Poli, Andrea

AU - Galli, Laura

AU - Riva, Agostino

PY - 2019

Y1 - 2019

N2 - : We evaluated the efficacy and safety of a two-drug regimen including dolutegravir (DTG) and unboosted atazanavir (uATV) in 151 HIV-1 infected patients with HIV-RNA of more than 50 copies/ml. During a median follow-up of 62 (42-97) weeks, two virological failures (1%) and 13 treatment discontinuations (9%) occurred; the 48-week probability of virological failure was 0.8% (95% confidence interval 0.2-5.6%). Switch to DTG + uATV may represent a boosting and transcriptase reverse inhibitors sparing otion in individuals with long exposure to antiretroviral therapy and risk of cardiovascular disease.

AB - : We evaluated the efficacy and safety of a two-drug regimen including dolutegravir (DTG) and unboosted atazanavir (uATV) in 151 HIV-1 infected patients with HIV-RNA of more than 50 copies/ml. During a median follow-up of 62 (42-97) weeks, two virological failures (1%) and 13 treatment discontinuations (9%) occurred; the 48-week probability of virological failure was 0.8% (95% confidence interval 0.2-5.6%). Switch to DTG + uATV may represent a boosting and transcriptase reverse inhibitors sparing otion in individuals with long exposure to antiretroviral therapy and risk of cardiovascular disease.

KW - Health Policy

KW - Infectious Diseases

KW - Pharmacology (medical)

KW - antiretroviral therapy

KW - dolutegravir

KW - dual therapy

KW - switch strategy

KW - Health Policy

KW - Infectious Diseases

KW - Pharmacology (medical)

KW - antiretroviral therapy

KW - dolutegravir

KW - dual therapy

KW - switch strategy

UR - http://hdl.handle.net/10807/139247

U2 - 10.1097/QAD.0000000000002188

DO - 10.1097/QAD.0000000000002188

M3 - Article

SN - 0269-9370

VL - 33

SP - 1256

EP - 1260

JO - AIDS

JF - AIDS

ER -

Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo